SBIR Phase I: Antiviral and Anti-inflammatory Live Biotherapeutics (COVID-19) — NSF Award to General Probiotics Inc (MN, $256,000)
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of new therapeutics against coronavirus SARS-CoV-2 and associated COVID-19. Few broad-spectrum antivirals exist, and vaccines are effective but strain-specific and require development time for ea
| Award title | SBIR Phase I: Antiviral and Anti-inflammatory Live Biotherapeutics (COVID-19) |
|---|---|
| Award ID | 2031154 |
| Awardee | General Probiotics Inc |
| City | SAINT PAUL |
| State | MN |
| Amount obligated | $256,000 |
| Principal investigator | Yiannis Kaznessis |
| Program | SBIR Phase I |
| Start date | 09/01/2020 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of new therapeutics against coronavirus SARS-CoV-2 and associated COVID-19. Few broad-spectrum antivirals exist, and vaccines are effective but strain-specific and require development time for each new strain. This project will engineer probiotics native to the upper respiratory tract of humans to serve as antiviral and antibacterial agents. These probiotics will inhibit v |
| Source | NSF Awards |
$799/mo
Try NSFGrants →